David R. Taft, Ph.D.
Program Director for Pharmaceutics Graduate Program David.Taft@liu.edu
Ph.D., Pharmaceutical Science, University of Connecticut, Storrs, CT
B.S., Pharmacy, University of Rhode Island, Kingston, RI
Dr. David R. Taft received his B.S. degree in pharmacy from the University of Rhode Island and his Ph.D. from the University of Connecticut. Following completion of a fellowship in pharmacokinetics at the University of North Carolina School of Pharmacy, Dr. Taft joined the faculty at LIU in 1994. Dr. Taft teaches a variety of courses, particularly in pharmacokinetics, in both the professional program in pharmacy (Pharm.D.) and the graduate programs (M.S. and Ph.D.) in pharmaceutics. In addition, he provides instruction in physical pharmacy, pharmacy compounding, pharmacy math, and other courses. His primary research area is pharmacokinetics, with an emphasis on preclinical evaluation of drugs and drug candidates. Dr. Taft’s laboratory has collaborated with numerous companies in projects ranging from characterizing renal drug excretion in rat-kidney models to drug formulation evaluation in preclinical and clinical studies. Dr. Taft is past recipient of the AACP New Investigators Award, the Long Island University David Newton Award for Excellence in Teaching, the AAPS New Investigator Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism and the University of Connecticut School of Pharmacy Distinguished Alumni Award.
The majority of my research is in the area of pharmacokinetics, the science that describes the time course of drug disposition by the body. Even more simply, it can be summarized as a study of what the body does to a drug. Pharmacokinetics involves mathematical characterization of drug absorption, distribution, metabolism, and excretion (ADME). My laboratory utilizes a combination of in vitro, in vivo, and in silico tools in our research, and we collaborate on various projects that focus on development of new therapeutic compounds, pharmacokinetic evaluation of marketed drugs, and application of modeling and simulation to predict pharmacokinetics in special populations.
Vidhi Shah, Robert A. Bellantone, and David R. Taft. Evaluating the Potential for Delivery of Irinotecan via the Buccal Route: Physicochemical Characterization and In Vitro Permeation Assessment Across Porcine Buccal Mucosa. AAPS Pharm Sci Tech. 2016 Jun 30. [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/27363416
Aruna Dontabhaktuni, David R. Taft, and Mayankbhai Patel. Gentamicin Renal Excretion in Rats: Probing Strategies to Mitigate Drug-Induced Nephrotoxicity. Pharmacology & Pharmacy 7:43-55,2016
Rami S. Komrokji, Azra Raza, Jeffrey E. Lancet, Chen Ren, David Taft, Manoj Maniar, Francois Wilhelm and Alan F. List. Phase I Clinical Trial of Oral Rigosertib in Patients with Myelodysplastic Syndrome. British Journal of Haematology 162:517-254, 2013 http://www.ncbi.nlm.nih.gov/pubmed/23789936
Michael P. White, Mariana Babayeva, David R. Taft, and Manoj Maniar. Determination of Intestinal Permeability of Rigosertib (ON 01910.Na, Estybon™): Correlation with Systemic Exposure. Journal of Pharmacy and Pharmacology 65:960-969, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23738723
Mitalee Tamhane, Manoj Maniar, Chen Ren, Kenza E. Benzeroual and David R. Taft. Disposition of ON 01210.Na (Ex-RAD®), a Novel Radioprotectant, in the Isolated Perfused Rat Liver: Probing Metabolic Inhibition to Increase Systemic Exposure. Journal of Pharmaceutical Sciences 102:732–740, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23212688
Amy W. Chun, Robert E. Freshwater, David R. Taft, Amanda M. Gillum and Manoj Maniar. Effects of Formulation and Route of Administration on the Systemic Availability of Ex-RAD, a New Radioprotectant, in Preclinical Species. Biopharmaceutics and Drug Disposition 32(2):99-111, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21341279
Antoinette Ajavon, Peter Bonate, and David R. Taft. Renal Excretion of Clofarabine: Assessment of Dose-linearity and Role of Renal Transport Systems on Drug Excretion. European Journal of Pharmaceutical Sciences 40(3):209-216, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20347037
Mitalee Tamhane, Ananthsrinivas R. Chakilam, Andrew Jayaraj, Vineet Thakkar, and David R. Taft. Comparative Renal Excretion of VX-702, a Novel P38 Mapk Inhibitor, and Methotrexate in the Perfused Rat Kidney Model. Drug Development and Industrial Pharmacy 36(3):315-322, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20170280
Amy W. Chun, Stephen C. Cosenza, David R. Taft and Manoj Maniar. Preclinical Pharmacokinetics and In Vitro Activity of ON 01910.Na, a Novel Anti-cancer Agent. Cancer Chemotherapy and Pharmacology 65(1):177-86, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19466411
David R. Taft, Ishani A. Savant, Aruna Dontabhaktuni, Mariana Babayeva and Tomoko Nakatani-Freshwater. Application of the Isolated Perfused Rat Kidney Model to Assess Gender Effects on Drug Excretion. Drug Development and Industrial Pharmacy 32(8):919-28, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16954104
Tomoko Nakatani-Freshwater, Mariana Babayeva, Aruna Dontabhaktuni, and David R. Taft. Effects of Trimethoprim on the Clearance of Apricitabine, a Deoxycytidine Analog Reverse Transcriptase Inhibitor, and Lamivudine in the Isolated Perfused Rat Kidney. Journal of Pharmacology and Experimental Therapeutics 319(2):941-947, 2006. http://www.ncbi.nlm.nih.gov/pubmed/16926264
Malaz A. AbuTarif and David R. Taft. Simulation of the Pharmacokinetic Profile of Methazolamide in Blood: Effect of Carbonic Anhydrase Binding on Drug Disposition. Pharmaceutical Research 19:551-555, 2002. http://www.ncbi.nlm.nih.gov/pubmed/12033394